Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Pharma-Bio Serv (PBSV) over the last 16 years, with Q4 2025 value amounting to -$856665.0.

  • Pharma-Bio Serv's Cash from Investing Activities fell 59941.99% to -$856665.0 in Q4 2025 from the same period last year, while for Oct 2025 it was -$1.5 million, marking a year-over-year decrease of 775.41%. This contributed to the annual value of -$1.5 million for FY2025, which is 775.41% down from last year.
  • Latest data reveals that Pharma-Bio Serv reported Cash from Investing Activities of -$856665.0 as of Q4 2025, which was down 59941.99% from $1.6 million recorded in Q3 2025.
  • Over the past 5 years, Pharma-Bio Serv's Cash from Investing Activities peaked at $7.3 million during Q4 2023, and registered a low of -$8.2 million during Q1 2023.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$1385.5 (2022), whereas its average is -$288407.0.
  • Over the last 5 years, Pharma-Bio Serv's Cash from Investing Activities had its largest YoY gain of 6509947.26% in 2023, and its largest YoY loss of 119930994.15% in 2023.
  • Quarter analysis of 5 years shows Pharma-Bio Serv's Cash from Investing Activities stood at $881.0 in 2021, then plummeted by 1477.64% to -$12137.0 in 2022, then skyrocketed by 60469.54% to $7.3 million in 2023, then plummeted by 97.66% to $171532.0 in 2024, then crashed by 599.42% to -$856665.0 in 2025.
  • Its last three reported values are -$856665.0 in Q4 2025, $1.6 million for Q3 2025, and -$3.2 million during Q2 2025.